Last reviewed · How we verify
platinum-based dual-agent chemotherapy
Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells.
Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells. Used for Advanced or metastatic solid tumors (specific indication pending phase 3 trial results).
At a glance
| Generic name | platinum-based dual-agent chemotherapy |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Platinum-based chemotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Platinum agents (such as cisplatin, carboplatin, or oxaliplatin) form covalent adducts with DNA, causing interstrand and intrastrand crosslinks that prevent DNA replication and transcription. When combined as a dual-agent regimen, the two components may target different pathways or enhance each other's cytotoxic effects, potentially overcoming resistance mechanisms and improving efficacy in solid tumors.
Approved indications
- Advanced or metastatic solid tumors (specific indication pending phase 3 trial results)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
- Anemia
Key clinical trials
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (PHASE3)
- Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer (PHASE2)
- SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (PHASE2, PHASE3)
- A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive (PHASE3)
- Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer (PHASE2)
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (PHASE3)
- Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: